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Thymidine phosphorylase (TP) catalyses the reversible
phosphorolytic cleavage of thymidine, deoxyuridine and their
analogues to their respective bases and deoxyribose 1-phosphate.
This enzyme is widely expressed in human cells and tissues,
including leukocytes and platelets, where it may play a role in
thymidine homeostasis (Zimmerman and Seidenberg, 1964; Shaw
et al, 1988; Fox et al, 1995). A number of studies have shown that
TP is identical to the angiogenic factor platelet-derived endothelial
cell growth factor (PD-ECGF) (Ishikawa et al, 1989; Moghaddam
and Bicknell, 1992; Miyadera et al, 1995). 
TP has also been shown to possess angiogenic activity in vivo
and chemotactic activity in vitro (Brown and Bicknell, 1998).
Moghaddam et al (1995) have previously shown that TP-transfected
MCF7 tumours grew faster in nude mice than untransfected
tumours. However, in the latter study, the authors did not examine
whether TP transfection modified angiogenesis in the tumours they
investigated for growth. 
Histological analysis of a variety of human tumours including
bladder (O’Brien et al, 1995), breast (Fox et al, 1996),
oesophageal (Igarashi et al, 1998), gastric (Takebayashi et al,
1996a) and colorectal (Takebayashi et al, 1996b) cancers showed
elevated TP tumour levels compared with levels in non-neoplastic
counterparts. TP has been shown to be correlated with microvessel
density in head and neck cancer (Giatromanolaki et al, 1998) and
renal cell carcinoma (Imazono et al, 1997). In addition, TP seems
to play a role in invasion and metastasis in gastric cancer (Maeda
et al, 1997), bladder cancer (Kubota et al, 1997) and colorectal
cancer (Takebayashi, 1996b). 
On the other hand, TP plays a crucial role in the pharmacology
of fluoropyrimidines. More precisely, TP is needed to activate
5´DFUR into 5FU and for the conversion of 5FU into 5-fluoro-
2´-deoxyuridine. Several in vitro studies have provided evidence
that TP transfection in cancer cells could sensitize them to 5FU
(Schwartz et al, 1995) and/or to 5´DFUR (Patterson et al, 1995;
Evrard et al, 1999). In addition, Sawada et al (1998) recently
demonstrated that the induction of TP activity in vivo by
taxol/taxotere enhance the efficacy of 5´DFUR and Capecitabine,
a new promising oral 5FU prodrug (Budman et al, 1998). 
Tumoral TP thus appears to play a dual role by being involved
in neoangiogenesis and by activating 5FU prodrugs at the tumoral
target site. It was felt that further work was necessary to investi-
gate more thoroughly these potential physiological and pharmaco-
logical roles of TP. In the present study, a rat carcinoma cell line
(PROb) was transfected with TP/PD-ECGF cDNA in order to
study the effect of the overexpression of this enzyme (1) on the
sensitivity of cells to 5´DFUR and 5FU in vitro and (2) on tumour
growth in vivo by using a syngenic tumour model in the BDIX rat. 
MATERIALS AND METHODS 
Chemicals 
5´DFUR (doxifluridine), MTT (3-[4,5-dimethylthiazol-2-yl]-
2, 5-diphenyltetrazolium bromide) were purchased from Sigma 
(St Quentin Fallavier, France). 5FU (Roche, Neuilly, France) was
obtained commercially  and from the pharmacy at the Cancer
Center. 
Cell lines 
DHD/K12/PROb (PROb) cells represent a colon carcinoma cell
line originating from a chemically induced colon cancer in BDIX
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progressive and metastatic tumours in syngenic hosts (Caignard
et al, 1985). Cells were cultured at 37˚C in a fully humidified
5% CO2 atmosphere in DMEM medium supplemented with
10% FCS, 2 mM glutamin, 600 mg l–1 insulin, 50 000 U l–1
penicillin, 80 mM streptomycin and 500 mg l–1 transferrin. All
transfectants were cultured in the same medium supplemented
with 100 mg ml–1 of geneticin. 
Transfection of TP cDNA into PROb cells 
The pcDNA1neo plasmid vector containing a full-length TP/PD-
ECGF cDNA (pCMVTP) was kindly provided by Dr R Bicknell
(University of Oxford). 
PROb cells were transfected with the pCMVTP or the
pcDNA3nco, as a control, by electroporation. After transfection,
cells were selected for neomycin resistance by treating them with
100 mg ml–1 G418 (Geneticin; Sigma). Several TP clones (trans-
fected with pCMVTP) and neo clones (controls transfected by
pcDNA3neo) were randomly selected. For these clones, TP activity
and 5’DFUR and 5FU sensitivities were tested. 6 TP and 2 control
clones (neo) were kept for studies on cytotoxicity. The 6 TP clones
were selected on the basis of the wide range of TP expression
which was provided. 
Pyrimidine nucleoside phosphorylase (PYNPase)
activity assay 
There are 2 distinct PYNPase present in normal and neoplastic
cells: TP, for which the major substrate is thymidine, and uridine
phosphorylase (UP) which is responsible for the reversible catal-
ysis of uridine to uracil. As both TP and UP are responsible for the
activation of 5’DFUR into 5FU, PYNPase activity was measured
in the analysed samples. To determine the respective activity rela-
tive to each enzyme we applied, in the reaction mixture, specific
inhibitors for TP (TP inhibitor Tahio Japan) and for UP (phenylse-
lenerylacycouridine, PSAU). PSAU was kindly provided by Dr M
El Kouni, University of Alabama at Birmingham. 
The analytical method we used for the determination of
PYNPase activity was derived from Kubota et al (1997). Cultured
cells (107) were homogenized in 500 ml of lysis buffer consisting of
50 mM Tris-HCI (pH 6.8), 1% Triton X-100, 2 mM phenylmethyl-
sulfonyl fluoride (PMSF) and 0.02% mercaptoethanol. The samples
were centrifuged at 105 000 g for 30 min at 4˚C. Supernatants
(0.8 mg proteins ml–1) were incubated for 4 h at 37˚C with 10 mM
5´DFUR and 180 mM potassium phosphate (pH 7.4) ± 100 mM of
TPI or PSAU. The reaction was stopped by the addition of 360 ml of
ice-cold methanol to the 120 ml of the reaction mixture. After
removal of the precipitate by centrifugation, an aliquot of the reac-
tion mixture was applied to the HPLC column (Licrospher 100 – RP
18). The elution buffer consisted in 50 mM phosphate buffer (pH
6.8) containing 10% methanol. The amount of 5FU produced was
measured by UV detection (262 nm). TP activity was expressed as
nmoles of 5FU converted mg–1 of protein h–1. Protein concentration
was determined by using the method of Bradford (1976). 
In vitro cytotoxicity assay (MTT assay, Carmichael et al,
1987) 
Cells (1500 cells well–1) were seeded in 96-well microtitration
plates. Culture conditions were as described above. Plates were
incubated for 24 h at 37˚C, 5% CO2. Then, cells were treated for
72 h with different concentrations of 5FU or 5´DFUR (5 wells per
drug concentration). Thereafter, cells were washed with PBS and
incubated with MTT. After 2 h of exposure, MTT was released
and fixation was revealed by the addition of 100 ml of DMSO.
Absorbance at 450 nm was measured using a microplate reader
(Labsystems, Helsinki Finland). Cell sensitivity to tested drugs
was expressed by IC50 (concentration leading to 50% cell
survival). The cytotoxicity assay was performed in quadruplicate. 
TP determination by RT-PCR 
Reverse transcription of 1 mg of RNA (extracted by RNA now,
Ozyme) was done using expand reverse transcriptase
(Boehringer). Primers for PCR of human TP were 5´-GCTTC
GTGGCCGCTGTGGTG-3´ and 5´-TCTGCTCTGGGCTCTG-
GATGA-3´. The amount of cDNA used in each reaction was 5 ml
for each sample and was amplified using Taq DNA polymerase in
35 cycles, each cycle consisting of 1 min at 94˚C, 1 min at 64˚C,
and 1 min at 72˚C. Gels were photographed using the Imagemaster
system (Pharmacia). 
In vivo study 
For all of the experiments we used adult BDIX male rats weighing
180–250 g (IFFA CREDO, l’Arbresle, France). All of the surgical
procedures and care given to the animals were in accordance with
institutional guidelines and the UKCCCR guidelines (UKCCCR,
1998).
Tumour growth 
Tumours were generated by subcutaneous or subcapsular injection
of PROb neo (controls) or PROb TP cells (tumoral cells trans-
fected with TP): 1.5 ´ 106 cells in 100 ml of PBS, cells counted and
apparent viability checked under microscope. As concerns subcap-
sular injections this was done in the liver capsule of the right lobe.
The TP6 expressing the highest PYNPase activity was selected for
these in vivo experiments. For both sub-cutaneous and hepatic
tumours, 2 independent experiments were conducted, and 10 rats
per condition were used in each experiment. For subcutaneous
tumours, tumour size was determined every 3 days over 1 month
with a calliper and tumoral volume was estimated by using the
following equation, A ´ B2 ´P /6, where A is tumour length and B
is tumour width (Auerbach et al, 1978). For liver tumours, in each
experiment, rats were sacrificed at day 12 and day 20 and tumours
were excised to determine the tumoral volume, by using the same
equation as that applied for calculating the subcutaneous tumours. 
Tumour angiogenesis 
Tumour angiogenesis was evaluated by microvessel density. 2
cryostat sections per subcutaneous or subcapsular tumour, of about
6 mm thickness, were mounted on microscope slides. Samples
were immediately fixed in formaldehyde 3.7% for 10 min and then
rinsed twice with PBS for 5 min. Slides were incubated in
methanol/0.3% H2O2 for 30 min to inactivate endogenous peroxy-
dase activity. After rinsing in PBS, the samples were covered for
10 min with goat serum, then sections were incubated with a
1:2000 dilution of primary anti-Von Willebrand factor, factor VIII,
(sheep anti-rat IgG polyclonal antibody from Tebu, Cedarlane,
Ontario, Canada) in PBS 0.4% BSA for 1 hour. Sections were then
exposed to the bridging antibodies (rabbit anti-sheep antibody) in
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peroxydase anti-peroxydase complex for 30 min. After rinsing in
PBS, the samples were incubated with a solution of diaminobenzi-
dine for 5 to 10 min. Then, tissue sections were counterstained
with Harris’ haematoxylin, dehydrated with ethanol and toluene
solutions and permanently mounted. 
Image analysis 
The image analysis system, Visiolab 1000 (Biocom, Les Ulis,
France), comprises a PC/AT compatible microcomputer, a real
time imaging processor, a control monitor and a colour high defin-
ition monitor. The microscope (Nikon) was equipped with a video
colour camera DXC 101 from Sony and with a precision x, y stage
with a 1 mm step size under computer control. Positive cells were
stained with a polyclonal antibody and revealed by an immunoper-
oxidase method. Negative cells were only coloured by Harris’s
haematoxylin. This counterstain was selected because it offers a
satisfactory spectral separation from diaminobenzidine (DAB).
Slides were first analysed at a magnification of 0.97 mm pixel–1
(microscopic magnification 16 ´) to delimit manually the cryostat-
section and for an overall view of the tumour and counterstain
intensity. The sections were then analysed under computer control
at a microscopic magnification of 40 ´. The program automati-
cally presents to the user an area randomly selected inside the
delimited zone. The co-ordinates of each analysed field were
memorized so that the fields can be quickly revisited. 10 fields
were analysed for 1 given tumour sample. The program provides
for each selected field the percentage of cytoplasmic per surface
area showing positive immunostaining. At the end of the analysis
the average of the percentage of labelled cells per analysed surface
and all analysed fields were calculated by the program. 
Statistical analysis 
Plots of linear regression were done to test the correlation between
fluoropyrimidine cytotoxic activity (IC 50) and cellular PYNPase
activity and to test the correlation between endothelial cell staining
and tumour volume. ANOVA analyses were performed to evaluate
the effect of time on subcutaneous tumour growth. 
RESULTS 
Expression of human TP in PROb cells 
It was found that the growth rate of the TP transfected PROb cells
did not vary from that of the parental cells or that of neo trans-
fected cells (control cells). The levels of PYNPase activity (nmol
mg–1 proteins h–1) ranged from 130 (neol clone, control) to 412
(TP6 clone) (Figure 1). The use of specific inhibitors of UP and TP
showed that in the neo clones, PYNPase activity was mainly due to
UP (108 nmol mg–1 protein h–1 in UP and ND in TP), whereas in
the TP clones TP activity formed the bulk of PYNPase activity
(366 nmol mg–1 protein h–1 in TP and 46 nmol mg–1 protein h–1 in
UP for TP6 clone). 
In vitro cytotoxicity 
Cytotoxic effects of 5¢DFUR, and to a lesser extent those of 5FU,
were enhanced in TP clones as compared to control cells (Table 1).
As compared to controls, TP6 was found to be 10-fold and 3.3-fold
more sensitive to 5¢DFUR and 5FU, respectively. Moreover, for
the different tested clones (6 TP and 2 neo), there was a highly
significant correlation between PYNPase activity and in vitro
sensitivity to 5¢DFUR (r2 = 0.91, P = 0.0002, n = 8, Figure 2A) 
and, to a lesser extent, to 5FU (r2 = 0.49, P = 0.053, n = 8, 
Figure 2B).
In vivo growth 
For hepatic tumours (Figure 3), in both experiments, the size of
TP6 tumours was smaller than controls at the beginning of the
observation phase. Growth dynamics of TP tumours was always
higher than that of controls. More precisely, the size of TP6
tumours were smaller than controls at the start of the observation
phase in both cases and reached a similar size than control in one
case and overpassed control tumour in the other case. 
Results of 2 independent experiments are shown in Figure 4 for
subcutaneous tumours. TP transfection appears to confer a growth
kinetic advantage shown by a steep growth slope up to day 15
(Figure 4A). A second experiment confirmed that growth of TP6
tumours was higher than controls (Figure 4B). However, in both
experiments, growth curves merged for TP6 and control tumours
after 2 weeks of follow-up. 
Impact of thymidine phosphorylase surexpression 441
British Journal of Cancer (2001) 85(3), 439–445 © 2001 Cancer Research Campaign
0
100
200
300
400
500
P
Y
N
P
a
s
e
 
a
c
t
i
v
i
t
y
 
(
n
m
o
l
 
m
g
–
1
h
–
1
)
PROb neo1 neo2 TP1 TP2 TP3 TP4 TP5 TP6
Figure 1 PYNPase activity in parental PROb cells and in different neo and
TP clones. Neo cells are cells transfected with an empty vector. PYNPase
activity was measured as described in ‘Materials and Methods’. Each value
represents the mean ± SD of 4 independent experiments 
Table 1 Sensitivity to 5FU and 5¢DFUR of TP transfected cells 
5FU IC50 5¢DFUR IC50
PROb 0.42±0.26 12.95 ± 8.9 
neo1 0.46±0.28 13.05 ± 2.7 
neo2 0.25±0.08 8.73 ± 3.4 
TP1 0.14±0.05 1.41 ± 0.6 
TP2 0.13±0.04 1.13 ± 0.28 
TP3 0.12±0.03 1.8 ± 0.32 
TP4 0.12±0.06 1.98 ± 0.62 
TP5 0.2±0.09 1.14 ± 0.42 
TP6 0.14±0.06 1.02 ± 0.39 
Parental cells or clones were incubated for 72 h with different concentrations
of 5FU or 5¢DFUR. Cell sensitivity was revealed using the MTT test as
described in ‘Materials and methods’. Data, expressed as the concentration
of the drug leading to 50% cell survival (IC50), are means ± SE of 4 different
experiments. PROb are parental cells and neo are cells transfected with an
empty vector. TP expression in growing tumours 
Analysis of human TP mRNA (Figure 5) shows that the expres-
sion of the transgene was always found in TP6 tumours, even after
1 month of subcutaneous growth in BD IX rats. 
Analysis of angiogenesis 
Histological sections of neo2 and TP6 tumours were stained for
the presence of factor VIII, a specific marker of endothelial cells.
The staining of TP6 and neo2 tumours was compared for tumours
of similar volumes (Table 2). Staining of TP6 tumours for
endothelial cells was always higher than controls. There was a
tendency (P = 0.10) to find a higher staining ratio in tumours of
small volume and, vice versa, the staining ratio was reduced as
tumours increased in size (Figure 6). 
DISCUSSION 
Previous studies have already demonstrated the enhancement of
5¢DFUR cytotoxicity conferred by TP transfection (Patterson et al,
1995; Schwartz et al, 1995; Kato et al, 1997; Evrard et al, 1999).
However, a discrepancy still exists regarding the effects of TP
transfection on 5FU activity with some authors reporting an
increase in 5FU cytotoxicity (Schwartz et al, 1995; Evrard et al,
1999) whereas others showed to no change (Patterson et al, 1995;
Kato et al, 1997). The present investigation was conducted on a rat
colon carcinoma cell line, PROb, transfected with TP leading to
transfected cells expressing a range of TP activity. By using this
model it was observed that the cytotoxicity of the tested fluoropy-
rimidines was dependent upon the cellular level of PYNPase
activity. Taking into account the different PROb TP clones, there
was a significant correlation between PYNPase activity and drug
sensitivity for both 5¢DFUR and 5FU with, however, a stronger
correlation for 5¢DFUR (P = 0.0002) than for 5FU (P = 0.053).
TP6 clone was the clone expressing the highest TP activity. This
clone was found to be 10-fold and 3.3-fold more sensitive than
control cells to the action of 5¢DFUR and that of 5FU, respec-
tively. These TP-related cytotoxicity enhancements are relatively
modest as compared to those reported previously by Evrard et al
(1999). These authors found a maximal 40-fold decrease in the
5¢DFUR IC50 in TP transfected LS174T human colon carcinoma
cells. These results were based on a cellular TP overexpression
reaching 800 pmol mg h–1. In contrast, overexpression of TP
leading to maximal activity around 400 pmol mg h–1 (TP 6 clone)
was obtained in the present study. However, this latter level of TP
activity more closely reflects the range of TP activity encountered
442 S Marchetti et al 
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Figure 2 Correlation between PYNPase activity and cytotoxic activity of 5¢DFUR (A) and cytotoxic activity of 5FU (B) in 6 TP and 2 neo clones (as defined in
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Figure 3 Effect of TP overexpression on hepatic tumour growth. Tumours were generated by sub-capsular injection of neo2 or TP6 cells into the liver of
syngenic BD IX rats (3 animals in each group). Rats were sacrificed at 2 different times and tumour size was determined as described in the ‘Materials and
methods’ section. (A) and (B) are 2 independent experiments; in experiment (A) mean values for the coefficient of variation were 35% for neo and 59% for TP;
in experiment (B) mean values for the coefficient of variation were 53% for neo and 76% for TP in human tumours (Ishikawa et al, 1998). Overall, this part of the
present results strengthens the role of TP regarding the cytotoxic
activity of 5¢DFUR and, to a lesser extent, that of FU. We recently
showed that biochemical attempts to modulate TP activity led to
increased efficacy of 5FU demonstrated in vitro and in vivo
(Ciccolini et al, 2000). TP represents a key step within the activa-
tion pathway of the new oral fluoropyrimidine capecitabine
(Budman et al, 1998). The present data combined with those of
other previous authors (Patterson et al, 1995; Schwartz et al, 1995;
Kato et al, 1997; Evrard et al, 1999) underscore the notion that the
efficacy of capecitabine and its intermediate 5¢DFUR may be
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Table 2 Factor VIII staining comparison between TP6 and neo2 tumours at similar volume 
Liver tumours Subcutaneous tumours 
Tumoral volume (mm3) TP6/neo2 staining ratio Tumoral volume (mm3) TP6/neo2 staining ratio 
6 1.5 5 3 
18 2.8 16 1.4 
20 1.9 80 1.5 
45 1.3 100 1.3 
Tumour sampling was done at day 12 or day 20 for tumours growing in liver and at variable times between day 8 and day
40 in subcutaneous tumours. Tumour angiogenesis was studied using an antibody raised against rat factor VIII, as
described in Materials and Methods. 
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Figure 4 Effect of TP overexpression on subcutaneous tumour growth.
Tumours were generated by subcutaneous injection of neo2 or TP6 cells into
the flanks of syngeneic BD IX rats (10 animals in each group). Tumour
volumes were measured as described in the ‘Materials and Methods’ section.
A and B are two independent experiments. Points = controls (neo 2 cells);
triangles = TP6 cells; statistical analysis (ANOVA) for experiment A: effect of
time, P < 0.001; effect of tumoral cell, P < 0.001; interaction time vs tumoral
cell, P < 0.001. Statistical analysis (ANOVA) for experiment B: effect of time,
P < 0.001; effect of tumoral cell, P = 0.06; interaction time vs tumoral cell, 
P = 0.31. Vertical bars indicate 95% confidence intervals 
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Figure 5 Detection of human TP mRNA in neo2 and TP6 cells and tumours
on different days. For details of experiments, see ‘Materials and Methods’
section 
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Figure 6 Effect of tumour size on the evolution of endothelial cell staining
ratio. Squares = liver tumours; triangles = subcutaneous tumours. Statistical
analysis on linearized relationship (r2 = 0.31, P = 0.10) strongly dependent upon intratumoral TP activity. A convincing
demonstration of the important role of TP towards the activity of
capecitabine in vivo was recently given by Ishikawa and
colleagues (1998). Using an animal model, the authors showed
that the cytotoxic efficacy against xenografted tumours was
directly related to TP tumoral activity. Interestingly, TP is over-
expressed in tumoral tissue as compared to normal counterpart
(Takebayashi et al, 1996). Upregulation of TP by pharmacological
means using IL1a, TNFa, IFNa (Eda et al, 1993), taxol (Sawada
et al, 1998) or by a gene transfer approach thus seems justified in
order to attempt to optimize treatment by capecitabine or 5¢DFUR. 
On the other hand, as stressed by Folkman (1996), experimental
arguments are still needed to establish the role of TP in tumour
angiogenesis. The other purpose of the present study was thus to
try to provide additional experimental data allowing an assessment
of the role of TP in tumour angiogenesis. To our knowledge, the
only in vivo study was reported by Moghaddam and co-workers
(1995) who transfected TP into MCF-7 breast carcinoma cells and
observed the growth of TP transfected xenografts into a nude mice
model. Based on these experimental conditions, the authors
concluded that the expression of TP markedly enhances tumour
growth in vivo. In addition, in the same report, these authors were
able to show that TP surexpression induced vascularization by
using the rat sponge angiogenesis assay and the freeze-injured skin
graft model. Thus, the major conclusions on the role of TP in
tumour growth and angiogenesis were obtained from different
experimental models. The present study aimed to analyse the
impact of TP overexpression on both tumour growth and neoan-
giogenesis using a single tumour model based on TP-transfected
rat colorectal tumour cells. Importantly, the animal model used in
the present study was a syngenic animal model. These syngenic
conditions seem more favourable than the immunodeficiency state
(nude mice) since they provide conclusions which can be extrapo-
lated more easily to normal physiological conditions. 2 sites of
tumour implantation were used in the present rat model with
subcutaneous area and liver. From in vitro data it was clear that TP
transfection did not modify the intrinsic growth rate of the PROb
transfected cells (results not shown). Data from liver and subcuta-
neous tumours indicate that TP-transfected tumours are smaller in
volume in the early stages of growth. We have no clear explana-
tion for this observation except the fact that the presence of human
TP may boost immunoreactivity against the TP tumours. From
liver tumour data the growth dynamics of TP tumours was higher
than that of controls but this dynamic aspect seems to be limited to
the early stages of tumour proliferation as shown in Figure 4A
which concerns subcutaneous tumours. Thus, in the light of the
present results, the impact of TP transfection on tumour growth
appears to be relatively modest and concerns only the initial stages
of tumour expansion. 
Interestingly, significant differences in factor VIII staining were
found in favour of TP-transfected tumours both in subcutaneous
tumours and liver tumours. However, close analysis of subcuta-
neous tumours indicated that the differences in microvessel
density were more evident in small tumours. This difference grad-
ually disappeared in tumours of larger size (Table 2). Thus, there is
a concordance of data between tumour growth and angiogenesis
with tumours of small volume only which presented an advantage
in tumour growth and neoangiogenesis when TP is overexpressed.
In order to explain these observations, the stability of TP expres-
sion was checked both in vitro (TP activity measurement) and in
vivo (RT-PCR determinations in fragments of subcutaneous
tumour) up to 6 weeks; TP expression was not found to be lost
during elapsed time in TP transfected tumours (Figure 5). Thus a
loss of TP expression over time cannot be advanced to explain the
progressive weakening of the impact of TP overexpression on both
tumour growth and neoangiogenesis. The sugar 2-deoxy-D ribose,
produced by the catalytic action of TP on thymidine is thought to
be responsible for the angiogenic property of TP. The sugar 2-
deoxy-D ribose can generate oxygen radical species which can
promote the secretion of stress-induced angiogenic factors (Brown
et al, 2000). The influence of 2-deoxy-D ribose on angiogenesis is
also attributable to a chemoattractant effect on endothelial cells
and not to the induction of cell proliferation (Brown and Bicknell,
1998). For this reason and in line with the present data, it could be
hypothesized that 2-deoxy-D ribose related-chemoattractant effect
influences neoangiogenesis in the early stages of tumour growth
by attracting new vessels to the tumour bed and favours enlarge-
ment of the tumour volume. After a given time, once the tumour is
irrigated and proliferates the TP-related production of 2-deoxy D
ribose can be of less importance in both neovessel proliferation
and tumour growth. It would be useful to confirm this hypothesis
in the light of additional more specifically designed experiments.
A practical application of the present observation is that targeting
TP for therapeutic purposes (Matsushita et al, 1999) would be
more desirable in the early stages of tumour growth when it has a
greater impact on the development of neoangiogenesis at the start
of tumour growth. 
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